<p><strong>Rheumatoid Arthritis</strong>: Recommended Adult Intravenous Dosage: When used in combination with DMARDs or as monotherapy the recommended starting dose is 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response.</p>

<ul>
	<li><strong>Patients less than 100 kg weight</strong>: 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response</li>
	<li><strong>Patients at or above 100 kg weight</strong>: 162 mg administered subcutaneously every week.</li>
</ul>

<p><strong>Giant Cell Arteritis</strong>: Recommended Adult Subcutaneous Dosage: The recommended dose of tocilizumab for adult patients with GCA is 162 mg given once every week as a subcutaneous injection, in combination with a tapering course of glucocorticoids. A dose of 162 mg given once every other week as a subcutaneous injection, in combination with a tapering course of glucocorticoids, may be prescribed based on clinical considerations. tocilizumab can be used alone following discontinuation of glucocorticoids. tocilizumab subcutaneous formulation is not intended for intravenous administration.<br />
<br />
<strong>Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)</strong>: Recommended Adult Subcutaneous Dosage: The recommended dose of tocilizumab for adult patients with SSc-ILD is 162 mg given once every week as a subcutaneous injection.<br />
<br />
<strong>Polyarticular Juvenile Idiopathic Arthritis</strong><br />
Recommended Intravenous PJIA Dosage Every 4 Weeks-</p>

<ul>
	<li>Patients less than 30 kg weight: 10 mg per kg</li>
	<li>Patients at or above 30 kg weight: 8 mg per kg</li>
</ul>

<p>Recommended Subcutaneous PJIA Dosage-</p>

<ul>
	<li>Patients less than 30 kg weight: 162 mg once every three weeks</li>
	<li>Patients at or above 30 kg weight: 162 mg once every two weeks</li>
</ul>

<p><strong>Systemic Juvenile Idiopathic Arthritis</strong><br />
Recommended Intravenous SJIA Dosage Every 2 Weeks-</p>

<ul>
	<li>Patients less than 30 kg weight: 12 mg per kg</li>
	<li>Patients at or above 30 kg weight: 8 mg per kg</li>
</ul>

<p>Recommended Subcutaneous SJIA Dosage-</p>

<ul>
	<li>Patients less than 30 kg weight 162 mg every two weeks</li>
	<li>Patients at or above 30 kg weight 162 mg every week</li>
</ul>

<p><strong>Cytokine Release Syndrome</strong><br />
Recommended Intravenous CRS Dosage-</p>

<ul>
	<li>Patients less than 30 kg weight: 12 mg per kg</li>
	<li>Patients at or above 30 kg weight: 8 mg per kg</li>
</ul>

<p>Alone or in combination with corticosteroids.<br />
<br />
<strong>General Dosing Information</strong>:</p>

<ul>
	<li>It is recommended that tocilizumab not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm3, platelet count below 100,000 per mm3, or who have ALT or AST above 1.5 times the upper limit of normal (ULN).</li>
	<li>tocilizumab doses exceeding 800 mg per infusion are not recommended in RA or CRS patients.</li>
</ul>